Authors

Deb Schrag, MD, MPH

Latest:

Dr Schrag on Neoadjuvant Chemotherapy and Selective Chemoradiation in Locally Advanced Rectal Cancer

Deb Schrag, MD, MPH, discusses findings from the phase 2/3 PROSPECT trial in patients with rectal cancer.

Joshua M. Bauml, MD, Perelman School of Medicine, University of Pennsylvania

Latest:

MET Inhibitors in NSCLC: Toxicity Management

Drs Joshua M. Bauml and Benjamin Levy highlight more common adverse events associated with MET inhibitors used to treat MET exon 14 skipping mutations in non–small cell lung cancer and share strategies to help manage patients on therapy.

Marc-Oliver Grimm, MD

Latest:

Dr Grimm on the Rationale for Conducting a Post-Hoc Analysis of ARASENS in mHSPC

Marc-Oliver Grimm, MD, discusses a post-hoc analysis of the ARASENS trial in metastatic hormone-sensitive prostate cancer.

Elizabeth A. Brem, MD

Elizabeth A. Brem, MD, is an associate clinical professor of medicine at the University of California Irvine.

Latest:

Dr Brem on the Potential Shift Away From Chemotherapy in Follicular Lymphoma

Elizabeth A. Brem, MD, highlights upcoming changes in the follicular lymphoma treatment paradigm that could move the field beyond chemotherapy.

Lydia Scarfò, MD

Lydia Scarfò, MD, is an assistant professor of internal medicine at the Università Vita-Salute San Raffaele; as well as a consultant hematologist at the Strategic Research Program on CLL

Latest:

Dr Scarfò on Early Safety Data With BGB-16673 in R/R CLL/SLL

Lydia Scarfò, MD, discusses early safety findings with the BTK degrader BGB-16673 in R/R CLL/SLL

Mack Roach III, MD

Mack Roach III, MD, is a Professor of Radiation Oncology and Urology in the Department of Radiation Oncology at the University of California San Francisco.

Stephanie J. Lee, MD, MPH

Latest:

Dr. Lee on the Results of the REACH3 Trial in Chronic GVHD

Stephanie J. Lee, MD, MPH, discusses the results of the phase 3 REACH3 trial in chronic graft-vs-host disease.

Andrew Coveler, MD

Latest:

Dr. Coveler on Replacing 5-FU With NUC-3373 in mCRC

Andrew Coveler, MD, discusses the potential clinical implications of positive data with NUC-3373 in metastatic colorectal cancer.

Lorenza Landi, MD

Latest:

Resistance Mechanisms and Molecular Testing in ALK Inhibitor–Treated NSCLC

Panelists discuss mechanisms of acquired resistance to ALK inhibition and how molecular testing guides sequencing strategies.

Jacob Moyer, BS

Jacob Moyer, BS, is a graduate researcher at Mayo Clinic.

Latest:

Real-World Data Support Nadofaragene Firadenovec Use in BCG-Unresponsive NMIBC: With Jacob Moyer, BS; and Mark D. Tyson, II, MD, MPH

Anna B. Halpern, MD

Latest:

Dr Halpern on Addressing Unmet Needs in Myelofibrosis

Anna B. Halpern, MD, discusses ongoing efforts to address unmet needs in patients with primary myelofibrosis.

Carrie L. Kitko, MD

Carrie L. Kitko, MD is an associate professor of pediatrics, Hematology/Oncology, Ingram Professorship in Pediatric Oncology, in the Department of Pediatrics, and the medical director of the Pediatric Stem Cell Transplantation Program at Vanderbilt University Medical Center, part of Vanderbilt Children's Hospital.

Latest:

Dr Kitko on Clinical Outcomes With Axatilimab According to Prior Lines of Therapy for Chronic GVHD

Carrie L. Kitko, MD, discusses outcomes with axatilimab in patients with chronic graft-vs-host-disease according to prior lines of therapy received.

Sushmita Gordhandas, MD

Latest:

Ovarian Cancer Prevention With the Opportunistic Salpingectomy: An Opportunity for Multidisciplinary Collaboration

A new understanding of pathogenesis has given rise to a promising prevention strategy for women at an average risk of developing ovarian cancer through surgical removal of the fallopian tubes, referred to as an opportunistic salpingectomy.

Dionisia Quiroga, DO, PhD

Dionisia Quiroga, DO, PhD, is a breast medical oncologist and assistant professor in the Division of Medical Oncology at The Ohio State University Comprehensive Cancer Center

Latest:

Dr Quiroga Shares Breast Cancer Insights

Dionisia Quiroga, DO, PhD, discusses breast cancer insights.

Seth Wander, MD, PhD

Latest:

Patient-Reported Outcomes From the SERENA-6 Trial of Camizestrant + CDK4/6 Inhibitor For Emergent ESR1m During First-Line Endocrine-Based Therapy and Ahead of Disease Progression in Patients With HR+/HER2– Advanced Breast Cancer

Seth Wander, MD, PhD discusses an overview of emerging data and evolving treatment strategies in advanced gastric and gastroesophageal cancers, with a focus on the role of biomarkers in guiding targeted and immunotherapy-based treatment. The presentation highlights clinical trial outcomes, testing considerations, and future directions shaping the personalized management of these patients.

Shuo Ma, MD, PhD

Latest:

Combination of Zanubrutinib + Venetoclax for Treatment-naive CLL/SLL With del(17p) and/or TP53: Preliminary Results From SEQUOIA Arm D

Preliminary results for treatment with zanubrutinib + venetoclax in patients with high-risk TN CLL/SLL with del(17p) and/or TP53 mutation showed Promising efficacy in a high-risk population with deep and durable responses according to data from arm D of the phase 3 SEQUOIA trial (NCT03336333).

Bradley Monk, MD

Latest:

Unmet Needs and Future Research Focus for Endometrial Cancer

Panelists discuss how addressing molecular, clinical, and access-related gaps remains essential for advancing endometrial cancer research and care.

Yiming Wu, PhD

Latest:

Dr Wu on the Role of METTL3-Mediated m6A Modification in CLL Progression

Yiming Wu, PhD, discusses a study identifying METTL3-mediated N6-methyladenosine modification as a key translational regulator of splicing factors, and how this mechanism contributes to the progression of chronic lymphocytic leukemia.

Vadim S. Koshkin, MD

Vadim Koshkin, MD, is an associate professor of medicine in the Division of Hematology and Oncology in the Department of Medicine at the University of California, San Francisco (UCSF) School of Medicine, as well as a genitourinary medical oncologist at the UCSF Helen Diller Comprehensive Cancer Center

Latest:

Bladder-Sparing Strategies and ctDNA-Guided Strategies Take Center Stage in MIBC: With Chandler Park, MD; and Vadim Koshkin, MD

Drs Park and Koshkin explore the clinical implications of the phase 3 NIAGARA trial for patients with resectable bladder cancer.

Pamela J. Sung, MD, PhD

Latest:

Differentiation Therapy in Acute Myeloid Leukemia: Not Just for APL Anymore

Pamela J Sung, MD, PhD, details differentiation therapy in acute myeloid leukemia, focusing on newer targets and preclinical evidence for a novel FLT3 combination.